<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>HEPA Homepage</title>
    <link rel="icon" type="image/x-icon" href="./images/favicon.png">
    <!-- BS CSS Stylesheet -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-4bw+/aepP/YC94hEpVNVgiZdgIC5+VKNBQNGCHeKRQN+PtmoHDEXuppvnDJzQIu9" crossorigin="anonymous">
    <link rel="stylesheet" href="style.css">
    <!-- BS JS Stylesheet -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-MrcW6ZMFYlzcLA8Nl+NtUVF0sA7MsXsP1UyJoMp4YLEuNSfAP+JcXn/tWtIaxVXM" crossorigin="anonymous" defer></script>
    <script src="script.js" defer></script>

</head>

<body>
    <!-- Navbar section -->
    <nav class="navbar navbar-expand-md bg-dark z-3">
        <div class="container navbar-dark">
            <a href="index.html" class="navbar-brand"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" fill="currentColor" class="bi bi-virus" viewBox="0 0 16 16">
                    <path d="M8 0a1 1 0 0 1 1 1v1.402c0 .511.677.693.933.25l.7-1.214a1 1 0 0 1 1.733 1l-.701 1.214c-.256.443.24.939.683.683l1.214-.701a1 1 0 0 1 1 1.732l-1.214.701c-.443.256-.262.933.25.933H15a1 1 0 1 1 0 2h-1.402c-.512 0-.693.677-.25.933l1.214.701a1 1 0 1 1-1 1.732l-1.214-.7c-.443-.257-.939.24-.683.682l.701 1.214a1 1 0 1 1-1.732 1l-.701-1.214c-.256-.443-.933-.262-.933.25V15a1 1 0 1 1-2 0v-1.402c0-.512-.677-.693-.933-.25l-.701 1.214a1 1 0 0 1-1.732-1l.7-1.214c.257-.443-.24-.939-.682-.683l-1.214.701a1 1 0 1 1-1-1.732l1.214-.701c.443-.256.261-.933-.25-.933H1a1 1 0 1 1 0-2h1.402c.511 0 .693-.677.25-.933l-1.214-.701a1 1 0 1 1 1-1.732l1.214.701c.443.256.939-.24.683-.683l-.701-1.214a1 1 0 0 1 1.732-1l.701 1.214c.256.443.933.261.933-.25V1a1 1 0 0 1 1-1Zm2 5a1 1 0 1 0-2 0 1 1 0 0 0 2 0ZM6 7a1 1 0 1 0-2 0 1 1 0 0 0 2 0Zm1 4a1 1 0 1 0 0-2 1 1 0 0 0 0 2Zm5-3a1 1 0 1 0-2 0 1 1 0 0 0 2 0Z" />
                </svg></a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#nav2">
                <div class="navbar-toggler-icon"></div>
            </button>
            <div class="collapse navbar-collapse" id="nav2">
                <ul class="navbar-nav">
                    </li>
                    <li class="nav-item">
                        <a href="index.html" class="nav-link active">HOME</a>
                    </li>
                    <li class="dropdown nav-item">
                        <button class="btn btn-dark dropdown-toggle" role="button" data-bs-toggle="dropdown" aria-expanded="false">
                            HEPION
                        </button>
                        <ul class="dropdown-menu dropdown-menu-dark">
                            <li class="nav-item">
                                <a href="hepion.html" class="dropdown-item">PRESS RELEASE</a>
                            </li>
                            <li class="nav-item">
                                <a href="about.html" class="dropdown-item">RENCOFILSTAT</a>
                            </li>
                        </ul>
                    </li>
                    <li class="nav-item">
                        <a href="article.html" class="nav-link">NASH ARTICLES</a>
                    </li>
                    <li class="nav-item">
                        <a href="landscape.html" class="nav-link">NASH LANDSCAPE</a>
                    </li>
                    <li class="nav-item">
                        <a href="result.html" class="nav-link">NASH RESULT</a>
                    </li>
                </ul>
            </div>
        </div>
    </nav>
    <!-- DIVIDER -->

    <div class="container my-2 access">
        <div class="row gap-4 justify-content-center text-center mt-4 px-3">
            <div class="card col-lg-5 col-12 bg-warning-subtle">
                <div class="card-body">
                    <h5 class="card-title h3">P2 ALTITUDE-NASH</h5>
                    <p class="card-text text-center">A Phase 2 MASH clinical trial, 4 months duration, three arm trial. A clinical collaboration with HepQuant.</p>
                    <p class="card-text text-start"> ‚úÖ 9/12/22 [Trial Initiation]:<br> Phase 2 Liver Function, Initiation Of Dosing.</p>
                    <p class="card-text text-start"> ‚úÖ 12/5/22 [Enrollment Completion]:<br> Early Completion Of Enrollment.</p>
                    <p class="card-text text-start"> ‚úÖ 5/22/23 [Trial Completion]:<br> Primary And Secondary Endpoints Met.</p>
                    <p class="card-text text-start"> üìú ALTITUDE Topline Data: <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-phase-2-altitude-nash-trial-achieves-primary-and-secondary-endpoints-including-improvement-in-liver-function-and-multiple-nash-biomarkers/" target="_blank" class="link-underline-light">MASH Biomarkers</a></p>
                    <p class="card-text text-start"> üìú ALTITUDE Additional Data: <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-announces-major-reductions-in-liver-stiffness-with-rencofilstat-treatment-in-17-week-phase-2-study-of-advanced-f3-mash-liver-disease/" target="_blank" class="link-underline-light">Fibroscan Results</a></p>

                </div>
            </div>
            <div class="card col-lg-5 col-12 bg-warning-subtle">
                <div class="card-body">
                    <h5 class="card-title h3">P2B ASCEND-NASH</h5>
                    <p class="card-text text-start">A Phase 2B MASH clinical trial, 12 months duration, four arm trial. A trial population with expected 336 subjects consisted of F2/F3, 60 days screening.</p>
                    <p class="card-text text-start"> ‚úÖ 8/31/22 [Trial Initiation]:<br>Phase 2B MASH Trial, Initiation Of Dosing.</p>
                    <p class="card-text text-start"> ‚úÖ 6/15/23 [First DSMB Meeting]:<br>Passing Of Key Safety Milestone.</p>
                    <p class="card-text text-start"> üö´ TBD [Enrollment Completion]</p>
                    <p class="card-text text-start"> üö´ TBD [First Interim Analysis]</p>

                </div>
            </div>
        </div>
    </div>

    <div class="container my-4 px-3 access">
        <table class="table table-dark text-center table-borderless mx-auto">
            <thead>
                <tr>
                    <th scope="col">2023 Qs</th>
                    <th scope="col">Cash</th>
                    <th scope="col">Assets</th>
                    <th scope="col">Liabilites</th>
                    <th scope="col">Net SH Equity</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td class="text-warning">Q4 2022</td>
                    <td>51M</td>
                    <td>60M</td>
                    <td>10M</td>
                    <td>49M</td>
                </tr>
                <tr>
                    <td></td>
                    <td class="text-danger">~8M</td>
                    <td class="text-danger">~11M</td>
                    <td class="text-danger">~2M</td>
                    <td class="text-danger">~12M</td>
                </tr>
                <tr>
                    <td><a href="https://s3.amazonaws.com/sec.irpass.cc/2652/0001583771-23-000007.htm" target="_blank" class="text-warning">Q1</a></td>
                    <td>43M</td>
                    <td>49M</td>
                    <td>12M</td>
                    <td>37M</td>
                </tr>
                <tr>
                    <td></td>
                    <td class="text-danger">~13M</td>
                    <td class="text-danger">~13M</td>
                    <td class="text-danger">~2M</td>
                    <td class="text-danger">~11M</td>
                </tr>
                <tr>
                    <td><a href="https://s3.amazonaws.com/sec.irpass.cc/2652/0001583771-23-000010.htm" target="_blank" class="text-warning">Q2</a></td>
                    <td>30M</td>
                    <td>36M</td>
                    <td>10M</td>
                    <td>26M</td>
                </tr>
                <tr>
                    <td></td>
                    <td class="text-danger">~11M</td>
                    <td class="text-danger">~11M</td>
                    <td class="text-danger">~2M</td>
                    <td class="text-danger">~10M</td>
                </tr>
                <tr>
                    <td><a href="https://s3.amazonaws.com/sec.irpass.cc/2652/0001583771-23-000013.htm" target="_blank" class="text-warning">Q3</a></td>
                    <td>19M</td>
                    <td>25M</td>
                    <td>8M</td>
                    <td>16M</td>
                </tr>
            </tbody>
        </table>
    </div>

    <div class="container my-4 access">
        <div class="row gap-4 justify-content-center px-3">
            <div class="card col-lg-5 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">Quarterly - Thoughts</h5>
                    <p class="card-text">- First half of 2023, $23M EQ equity has been dispense which equivalent to the outstanding level. Keep in mind 5 months have already past as of November 2023, therefore, we're in very critical levels with estimation ~$16M (Factoring latest PO).<br><br>
                        - As per restriction due to IB6, they have a maximum offerring potential of ~$24M. In which, ~$15M has already been allocated; ~$5M in stocks and ~$10M in warrants as per their offering.</p><br>
                    - As per IB6, the restriction also have a duration of 12 months. Given the offering closed in October 2023, it would implied possible offering amounting of the remaining ~$9M from now to October 2024.<br><br>
                    - Also need to take in consideration that, as warrants exercised, the OS will increased and will drastically decrease the SP needed to satisfy the $75M MC condition. Once lifted, their ability to raise substantial capital will greatly increase and with no more limitations.
                </div>
            </div>
            <div class="card col-lg-5 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">Latest Offering - Thoughts</h5>
                    <p class="card-text">- As per their latest SEC filing, it's confirmed the participator of their offering was <span class="text-danger fw-bold">Armistice Capital</span>, purchased both stocks and warrants.<br><br>
                        - Furthermore, confirmed by follow-up SEC filing. <span class="text-danger fw-bold">Armistice Capital</span> now held 397,607 in shares, 526,393 in Pre-funded warrants, and 1,960,786 in Series A&B warrants.<br><br>
                        - Unspoken of are the conditions within this offering agreement: As stated <span class="text-danger">"capped at either 4.99% or 9.99% beneficial ownership of the Company's issued and outstanding Common Stock (post-exercise)"</span><br>and<br> <span class="text-danger">"The warrants are subject to a beneficial ownership limitation of 4.99%</span></p><br>
                    - With the current stock position of <span class="text-danger fw-bold">Armistice Capital</span>, they're already at ~9% ownership. Given the current OS size of ~4.3M shares, they're restricted to exercise the pre-funded warrants.<br>Given the latest S-1 filing, it seems Series A & B warrants will be traded with HEPA's receiving a maximum proceeds of ~$10M.
                </div>
            </div>
        </div>
    </div>

    <div class="container my-4 access">
        <div class="row px-3">
            <div class="card col-lg-10 col-12 p-0 mx-auto">
                <div class="card-header fw-bold">PR - September 21, 2023</div>
                <div class="card-body">
                    <h5 class="card-title mb-2 text-center">Aurinia Pharmaceuticals today announced that its Board of Directors has appointed Dr. Robert T. Foster to the Board. MKT Capital submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board.</h5>
                    <a href="https://www.auriniapharma.com/investors-and-media/news-events/press-releases/detail/303/aurinia-board-of-directors-appoints-dr-robert-t-foster-as" target="_blank" class="btn btn-primary">Press Release Link</a>
                </div>
            </div>
        </div>
    </div>
    <div class="container my-4 access">
        <div class="row gap-4 justify-content-center px-3">
            <div class="card col-lg-10 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">Foster to AUPH BOD - Thoughts</h5>
                    <p class="card-text">- Strategic move from AUPH's major shareholders, strenghtening their position in selling the company to BP. Due to this ongoing tug-of-war between BOD and major shareholders, two BOD members has been resigned early this year.<br><br>
                        - Important to note, there has been reports of nepotism in AUPH's hierarchy involving the Chairman and CEOs, which lead to self-enrichment throught compensations and benefits. The largest shareholder of the time, ILJIN SNT, issued a statement to potentially re-established leadership for shareholders's benefits. Nonetheless, Robert Foster was one the mentioned for the role.<br><br>
                        - "ILJIN Chairman Issues Open Letter to Aurinia Shareholders" - <a href="https://www.businesswire.com/news/home/20190621005228/en/ILJIN-Chairman-Issues-Open-Letter-to-Aurinia-Shareholders" target="_blank" class="link-underline-light">Link</a><br><br>
                        - As per AUPH's SEC filing, it stated <span class="text-success">"the Company had $0.5 million and $6.4 million of current and non-current liabilities related to Dr. Foster, respectively"</span> and <span class="text-success">"Dr. Foster was entitled to receive 2% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.3% of net sales of voclosporin sold directly by the Company"</span>. Given the healthy relationship between Foster and the major shareholder, as well as, the founder of Voclosporin. His addition to AUPH's BOD is no stranger.<br><br>
                        "Foster's Royalty" - <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1600620/000160062023000040/auph-20230921.htm" target="_blank" class="link-underline-light">Link</a> / "Foster's Transactions" - <a href="https://finance.yahoo.com/sec-filing/AUPH/0001600620-23-000044_1600620" target="_blank" class="link-underline-light">Link</a>
                </div>
            </div>
        </div>
    </div>
    <div class="container my-4 access">
        <div class="row gap-4 justify-content-center px-3">
            <div class="card col-lg-5 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">Upcoming / Going Forward - Thoughts</h5>
                    <p class="card-text">
                        - Hepion will likely be acquired by interested parties. Given their balance sheet, they lack significant leveraging power in any deal discussions. This includes partnerships and collaborations.<br><br>
                        - The latest PO shows that HEPA is not willing to give up majority, this explain the restrictions placed on the "BUYER". Given the current outlook, it won't be long for the next PO. Possibly due to GLP pre-clinical study or ASCEND interim.<br><br>
                        - It's important to discuss the lack of communications and information. Information such as DSMB interims has been clearly misinformed; <br>
                        It was stated that two DSMB interim will be conducted, the first being NIMs and the second being biopsy. But as things unfolded, it seems that there will be 4 DSMB interims separated by safety & efficacy.<br><br>
                        - The first DSMB safety interim completed in June 2023, assuming the second being conducted in Q1/24.<br><br>
                        - The first DSMB efficacy interim is assumed to be in Q1/24 and the second to be in the second half of 2024. This would implied that the DBL is until patient trial completion.
                </div>
            </div>
            <div class="card col-lg-5 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">Upcoming Catalysts - Thoughts</h5>
                    <p class="card-text">
                        - GLP pre-clinical study will be interesting. If the study yield positive results, this will open the bridge between HEPA and some BP's investigational drugs. Overall, this may be overshadowed by their financial situation if they haven't find a solution by then.<br><br>
                        - The first DSMB interim, will once again, reiterate their previous studies and data unless they have some biopsy data available. The data will be 6-months duration, whereas ALTITUDE was already 4 months duration. Therefore, don't expect big surprise from the data.<br><br>
                        - Based on the current outlook, their options are very limited. It's not out of possiblities that some third-parties will further hinder them for take-over or acquisition.<br><br>
                        - Another possible option is to take on debts and loans. Having a credit-line will provide working capitals without issuing shares or increasing OS.
                </div>
            </div>
        </div>
    </div>

    <div class="container my-4 px-5 px-3 access">
        <table class="table table-dark table-borderless text-center mx-auto">
            <thead>
                <tr>
                    <th scope="col"></th>
                    <th scope="col">Subjects Dosed</th>
                    <th scope="col">Total Subjects Dosed</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>SAD</td>
                    <td>24</td>
                    <td></td>
                </tr>
                <tr>
                    <td>MAD</td>
                    <td>25</td>
                    <td></td>
                </tr>
                <tr>
                    <td>DDI</td>
                    <td>18(6)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Food Study</td>
                    <td>44</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Phase 2A 75MG</td>
                    <td>12(3)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Phase 2A 225MG</td>
                    <td>17(1)</td>
                    <td></td>
                </tr>
                <tr>
                    <td><a href="https://s3.amazonaws.com/sec.irpass.cc/2652/0001104659-22-065556.htm" target="_blank" class="text-warning">CP May 2022</a></td>
                    <td></td>
                    <td>159</td>
                </tr>
                <tr>
                    <td><a href="https://s3.amazonaws.com/sec.irpass.cc/2652/0001104659-22-109389.htm" target="_blank" class="text-warning">CP Oct 2022</a></td>
                    <td></td>
                    <td>+200</td>
                </tr>
                <tr>
                    <td><a href="https://hepionpharma.com/wp-content/uploads/2023/04/Hepion-Corporate-Slide-Deck-April-2023.pdf" target="_blank" class="text-warning">CP April 2023</a></td>
                    <td></td>
                    <td>+325</td>
                </tr>
                <tr>
                    <td><a href="https://s3.amazonaws.com/sec.irpass.cc/2652/0001104659-23-063036.htm" target="_blank" class="text-warning">CP May 2023</a></td>
                    <td></td>
                    <td>+425</td>
                </tr>
                <tr>
                    <td>ADME</td>
                    <td>*6</td>
                    <td></td>
                </tr>
                <tr>
                    <td>ALTITUDE</td>
                    <td>70</td>
                    <td></td>
                </tr>
                <tr>
                    <td>ASCEND</td>
                    <td>**257</td>
                    <td></td>
                </tr>
            </tbody>
        </table>
    </div>

    <div class="container my-4 access">
        <div class="row gap-4 justify-content-center px-3">
            <div class="card col-lg-10 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">ASCEND Enrollment - Thoughts</h5>
                    <p class="card-text">
                        - Based on Hepion's corporate presentations, we can somewhat estimate the enrollment progress. As per their latest presentation, they have dosed at least ~266 subjects, from the beginning of the trials to now.<br><br>
                        - With the known 70 subjects recruited for ALTITUDE, we can assume ~196 subjects were dosed from ASCEND. Given the ADME trial have never been disclosed to public, they may or may not been added to the total subjects dosed.<br><br>
                        - If we calculate, following their treatment to placebo ratio of 1:1:1:1, then the estimation of subjects currently enrolled into ASCEND is between ~253 to ~261 subjects or ~257 as average.<br><br>
                        - This information on the CP has not been updated since roughly April/May 2023. Would speculate they are somewhat near full enrollment if not yet completed. Given DBL, they may be blinded until everything is done and due.
                </div>
            </div>
        </div>
    </div>

    <div class="container my-4 access">
        <div class="row gap-4 justify-content-center px-3">
            <div class="card col-lg-10 col-12 p-0 text-center">
                <div class="card-header fw-bold bg-info">Speculations</div>
                <div class="card-body">
                    <h5 class="card-title">Past Events - Thoughts</h5>
                    <p class="card-text">
                        <span class="text-danger">Reverse Split</span> > This is a complicated one, given how we already know how things played out. HEPA at the time had insufficient unissued shares remaining, this came after many failed attempts to increase. Added on, was the obviously SP under the minimum bid price of $1. The main catalyst of the time was anticipation of ALTITUDE topline data to support the SP back into NASDAQ compilance. This fell short, given they had already decided to R/S roughtly a week prior.<br>
                        <span class="text-danger">This was actually very disappointing given how this unfolded. As stated, their deadline for their second extension ends on May 30th, and topline data were released May 22nd. By R/S, HEPA has secured themselves by sacrificing investors.<br>The main reasons that support HEPA's decision to R/S are; #1 To increased unissued shares, #2 Regain compliance, and #3 To raise a substantial offering with the availablity of unissued shares.<br>This is followed by a series of tragic events; #1 SP immediately plunged substantially, #2 Due to the plunge a week prior, ALTITUDE topline data did not support the SP higher than 75M MC, and #3 They did not immediately construct an offering or contingency plan to stabilize the SP which further plunged downward. </span><br><br>
                        <span class="text-danger">Rencofilstat's Data</span> > Pre-clinical and clinical studies have long proven Rencofilstat's place in MASH. The discussion is no longer the question of efficacy or safety, given they have already amassed and continue accumulating evidences. In short, Rencofilstat's efficacy is shown to be the greatest in late-stages of MASH, having the highest and greatest response and reductions. This gives Rencofilstat an edge over competitors who have only shown efficacy in early to mid stages of MASH. <br>Afterall, it's my beliefs that future treatments will be categories based on patients population. In other words, no one drug will dominate the market and be used for all stages of MASH, instead it will be divided by many drugs responsible for the different stages of MASH.<br><br>Based on the current outlook, given how Diabetes and MASLD/NASH are closely interlinked, early-mid stage of MASH will likely be saturated with GLP drugs/medication. This come from the aftermath of many successful GLP trial results with astounding results in liver fat reduction, which plays a pivotal role in early stages of MASH. With that being said, I see GLPs and Rencofilstat both at their respective end of the spectrum in MASH.
                </div>
            </div>
        </div>
    </div>

    <div class="container m-4 p-4 mx-auto">
        <div class="row justify-content-center">
            <div class="col-6">
                <div class="input-group mb-3">
                    <input type="text" class="form-control" id="key" placeholder="Access Password" aria-label="Password">
                    <input class="btn btn-primary" id="keyBtn" type="button" value="Submit">
                </div>
            </div>
        </div>
    </div>

    <!-- Due Diligence -->
    <div class="dd access">
        <div class="text-light h3 font-monospace text-center pt-4">Due Diligence Information</div>
        <div class="container-fluid py-4">
            <div class="row gap-4 justify-content-center px-3">

                <div class="card col-lg-5 col-md-8 col-12 bg-secondary-subtle">
                    <div class="card-body">
                        <h5 class="card-title h3 text-center">P2A AMBITION-NASH</h5>
                        <p class="card-text text-center">Designed to assess safety, tolerability, and pharmacokinetics of 75 mg and 225mg to F2 and F3 NASH subjects for 28 days.</p>
                        <p class="card-text text-start"> ‚úÖ 8/5/20 [Trial Initiation]:<br>Phase 2A Low Dose, Initiation Of Dosing.</p>
                        <p class="card-text text-start"> ‚úÖ 11/10/20 [Enrollment Completion]:<br>First Cohort P2A Enrollment Completion</p>
                        <p class="card-text text-start"> ‚úÖ 11/18/20 [First DSMB Meeting]:<br>Safety And Tolerability Of 75mg Dose Cohort.</p>
                        <p class="card-text text-start"> ‚úÖ 12/10/20 [Trial Checkpoint]:<br> Completed 75mg Dosing. Initiated 225mg Dosing.</p>
                        <p class="card-text text-start"> ‚úÖ 12/29/20 [Second DSMB Meeting]:<br>Safety And Tolerability Of 75mg Dose Cohort.</p>
                        <p class="card-text text-start"> ‚úÖ 5/6/21 [Enrollment Completion]:<br>Completed Final Recruitment.</p>
                        <p class="card-text text-start"> ‚úÖ 7/13/21 [Trial Completion]:<br>All Primary Endpoints Achieved.</p>
                        <p class="card-text text-start"> ‚úÖ 9/13/21 [Additonal Data]:<br>Additional Efficacy Data.</p>
                        <p class="card-text text-start"> üìú AMBITION 75mg Topline Data: <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-announces-positive-top-line-data-for-low-dose-crv431-in-phase-2a-ambition-clinical-trial-for-treatment-of-advanced-nash/" target="_blank" class="link-underline-light">Initial Biomarkers</a></p>
                        <p class="card-text text-start"> üìú AMBITION Topline Data: <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-announces-positive-topline-data-from-phase-2a-ambition-nash-trial-all-primary-endpoints-achieved/" target="_blank" class="link-underline-light">NASH Biomarkers</a></p>
                        <p class="card-text text-start"> üìú AMBITION Additional Data: <a href="https://hepionpharma.com/news/additional-data-from-hepion-pharmaceuticals-phase-2a-ambition-trial-further-strengthens-crv431-clinical-profile-and-paves-way-for-initiation-of-phase-2b-ascend-nash-clinical-program/" target="_blank" class="link-underline-light">Data Analysis</a></p>
                    </div>
                </div>

                <div class="card col-lg-5 col-md-8 col-12 bg-secondary-subtle">
                    <div class="card-body">
                        <h5 class="card-title h3 text-center">Safety & Tolerability Studies</h5>
                        <p class="card-text text-start"> ‚úÖ 6/25/18 [Trial Initiation]:<br>Phase 1 SAD, CRV431 In First In-Huamn Trial.</p>
                        <p class="card-text text-start"> ‚úÖ 7/23/18 [Preliminary Data]:<br>Phase 1/2A Safe And Well-Tolerated.</p>
                        <p class="card-text text-start"> ‚úÖ 8/7/18 [Analysis Data]:<br>Phase 1/2A Completion Of Data Analysis of 2nd Cohort.</p>
                        <p class="card-text text-start"> ‚úÖ 8/7/18 [Trial Completion]:<br>Completion Of Phase 1.</p>
                        <p class="card-text text-start"> ‚úÖ 10/30/18 [DDI Completion]:<br>Completion Of DDI Final Cohort Dosing.</p>
                        <p class="card-text text-start"> ‚úÖ 8/14/19 [MAD Study Initiation]:<br></p>
                        <p class="card-text text-start"> ‚úÖ 12/10/19 [MAD 2nd Dose Level]:<br></p>
                        <p class="card-text text-start"> ‚úÖ 2/12/20 [MAD 3rd Dose Level]:<br></p>
                        <p class="card-text text-start"> ‚úÖ 5/20/20 [MAD 4th Dose Level]:<br></p>
                        <p class="card-text text-start"> ‚úÖ 6/29/20 [MAD Final Dose Level]:<br></p>
                        <p class="card-text text-start"> ‚úÖ 9/1/20 [Trial Completion]:<br>Phase 1B MAD Final Dosing Completion.</p>
                        <p class="card-text text-start"> ‚úÖ 9/29/21 [Study Completion]:<br>All Endpoints Of Drug-Drug Interaction Study Met.</p>
                    </div>
                </div>

                <div class="card col-lg-10 col-12 p-0">
                    <div class="card-body bg-dark text-light">
                        <p class="card-text">
                            <span class="font-monospace">September 2023 </span> <span class="text-warning font-monospace"> üìÅ [Cancer Study] Novel Action in Liver Cancer</span>
                        </p>
                        <ul>
                            <li class="text-info">[The research involved a technique called ATAC-Seq (‚Äúassay for transposase-accessible chromatin with sequencing‚Äù) that determines what specific DNA sequences are in open or closed states]</li>
                            <li class="text-success">Hepion's ATAC-Seq experiments on two liver cancer cell lines revealed that Rencofilstat significantly changed the open-closed state of DNA. Approximately 4,500 sites were altered within one hour of treatment in both cell lines, which was slightly more than a chemotherapeutic compound, azacytidine, known to alter DNA structure.</li>
                            <li class="text-success">Rencofilstat predominantly closed DNA in the cell line in which it also suppressed cell growth, suggesting that the drug candidate's anti-cancer effect on the cells resulted in part from DNA closure and gene silencing.</li>
                            <li class="text-success">DNA sites that were opened by Rencofilstat were enriched for several well-known tumor suppressor genes.</li>
                            <li class="text-success">Anti-tumor effects of rencofilstat and other cyclophilin inhibitors observed in many preclinical studies have been attributed to several mechanisms, but changes in DNA accessibility and especially those that potentially limit oncogenesis have never before been reported for this class of drug.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">September 2023 </span> <span class="text-warning font-monospace"> üìÅ [Cancer Screening] Tested At The PRISM Lab At The Broad Of MIT and HARVARD</span>
                        </p>
                        <ul>
                            <li class="text-info">[Tested in a high through-put screen on 850 cancer cell lines spanning 28 types of cancer]</li>
                            <li class="text-success">26% of all tested cancer cell lines (220/850) spanning 86% of cancer cell types (24/28) were responsive to Rencofilstat.</li>
                            <li class="text-success">Genes known to be mutated in HCC or other types of cancer, including ATM, PTPRB, HNF1A, NOTCH1, ALK, TP63, IDH2 and MAP3K, were among the many genes identified to possibly influence the sensitivity of cells to Rencofilstat.</li>
                            <li class="text-success">Rencofilstat altered the immune cell composition of liver tumors in mice, suggesting an enhanced immune attack on the tumors</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">September 2023 </span> <span class="text-warning font-monospace"> üìÅ [Translational Study] Idiopathic Pulmonary Fibrosis</span>
                        </p>
                        <ul>
                            <li class="text-info">[Obtained diseased lung tissues from two individuals; PhenoSwitch Bioscience identified 1,953 uniqe proteins in the samples]</li>
                            <li class="text-success">Rencofilstat altered levels of between 8% and 28% of the 1,953 proteins identified in Precision cut lung slices (PCLusS).</li>
                            <li class="text-success">In combination with nintedanib, altered levels of 16-42%. In combination with pirfenidone, altered levels of 12-46%.</li>
                            <li class="text-success">Rencofilstat's suppression of fibrotic collagen production through cyclophilin B inhibition is one well-established mechanism.</li>
                            <li class="text-success">Rencofilstat alone shifted protein profiles more extensively than nintedanib and pirfenidone in most instances, and rencofilstat combinations were superior to every monotherapy.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">January 2023 </span> <span class="text-warning font-monospace"> üìÅ [Cancer Study] Preclinical Multiple Myeloma Studies</span>
                        </p>
                        <ul>
                            <li class="text-info">[Most of the experiments were performed by Diag2Tec (Montpellier, France), a contract research organization with expertise in MM]</li>
                            <li class="text-success">Rencofilstat exerted anti-cancer activity across a large panel of MM cell lines, and most potently, in combination with bortezomib, a proteosome inhibitor and first-line treatment for MM.</li>
                            <li class="text-success">The combination of rencofilstat and bortezomib produced 100% cytotoxicity in cell culture experiments across all 16 MM cell lines, including three lines that are characterized as bortezomib-resistant.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">January 2023 </span> <span class="text-warning font-monospace"> üìÅ [Cancer Study] Preclinical Studies In Combination With Proteosome Ihinitors</span>
                        </p>
                        <ul>
                            <li class="text-info">[A New Strategy to Increase Proteotoxic Stress in Prostate Cancer]</li>
                            <li class="text-success">The study showed that Rencofilstat could synergistically increase the proteotoxic stress and in vitro cancer killing properties of ixazomib.</li>
                            <li class="text-success">Neither drug alone at low concentrations caused proteotoxic stress or killed the cells. However, in combination they induced sustained proteotoxic stress and killed 70%-90% of the cancer cells (4 different cell lines) over two days. In contrast, the drug combination caused only mild, transient stress and no killing of the non-cancer cells.</li>
                            <li class="text-success">Certain isoforms of cyclophilins participate in the efficient synthesis and function of proteins and contribute significantly to cancer cell growth. Inhibiting those cyclophilins with Rencofilstat and impairing protein turnover with ixazomib together stressed the cells beyond a threshold and triggered their death.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">October 2022 </span> <span class="text-warning font-monospace"> üìÅ [Food Study] Food Effect With Rencofilstat</span>
                        </p>
                        <ul>
                            <li class="text-success">This study showed that taking rencofilstat with a high fat meal increases the absorption of this cyclophilin inhibitor and confirms the safety of the drug while providing the flexibility for patients to take rencofilstat with or without food.</li>
                            <li class="text-success">The increased absorption did not cause toxicity, and it is possible the increased exposure with food could enhance Rencofilstat's efficacy in those NASH and/or HCC patients who may be poor absorbers of the drug.</li>
                            <li class="text-success">The results from this well-controlled food effect study demonstrate that we can be comfortable with administration of rencofilstat under real-world, everyday conditions with or without a meal.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">January 2022 </span> <span class="text-warning font-monospace"> üìÅ [Cancer Study] Combination With An Immune Checkpoint Inhibitor, Synergistic Anti-Tumor Activity</span>
                        </p>
                        <ul>
                            <li class="text-success">Suggesting that Rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancer.</li>
                            <li class="text-success">Combination treatment of Rencofilstat plus anti-PD1 decreased tumor size by 69% at Day 28 and increased median mouse survival time by 26%.</li>
                            <li class="text-success">Treatment with either anti-PD1 or Rencofilstat alone in HCC model decreased tumor growth by 76% when tumorigenic cells were implanted into non-fatty livers but were not effective as monotherapies in fatty livers.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">November 2021 </span> <span class="text-warning font-monospace"> üìÅ [Cancer Study] FibroFind: Anti-Cancer In Liver Cancer Study</span>
                        </p>
                        <ul>
                            <li class="text-success">Rencofilstat was as effective at decreasing tumor burden as an anti-PD1 antibody immune checkpoint inhibitor, PD1 antibody, and produced more beneficial changes in tumor infiltrating cells compared to anti-PD1 antibody treatment.</li>
                            <li class="text-success">Treatment with Rencofilstat or an anti-PD1 antibody each decreased tumor size by 76%, while the Rencofilstat/anti-PDI antibody combination treatment decreased tumor size by 83%, compared to the vehicle treatment (no drug).</li>
                            <li class="text-success">Rencofilstat beneficially doubled the number of tumor-infiltrating CD4 and CD8 lymphocytes; also decreased the number of neutrophils in the tumors by 55%.</li>
                            <li class="text-success">Rencofilstat positively altered inflammatory and immune cell populations in the tumors, which is a cornerstone of modern cancer therapy.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">March 2021 </span> <span class="text-warning font-monospace"> üìÅ [Vivo Study] Antifibrotic Effects in DIAMONS Mouse Model</span>
                        </p>
                        <ul>
                            <li class="text-info">[In this study, our laboratory established NASH by feeding animals with a fat- and sugar-enriched Western diet for 34 weeks, followed by 8 weeks treatment with oral dosing of Rencofilstat or two comparator drugs, obeticholic acid and elafibranor.]</li>
                            <li class="text-success">We have conducted 9 individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of Rencofilstat in every one of these studies.</li>
                            <li class="text-success">The results obtained with the DIAMOND mouse experiment confirm, once again, that Rencofilstat is a potent antifibrotic agent.</li>
                            <li class="text-success">Fibrosis was reduced, as determined using Picrosirius Red staining, by 47% with Rencofilstat, 35% with Obeticholic Acid, and 37% with Elafibranor, relative to vehicle controls.</li>
                            <li class="text-success">Short course of Rencofilstat treatment can exert beneficial effects at an advanced stage of liver disease in a model having many similarities to human NASH.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">December 2020 </span> <span class="text-warning font-monospace"> üìÅ [Translational Study] CRV431 Potential Advantage In Liver Disease</span>
                        </p>
                        <ul>
                            <li class="text-success">Rencofilstat, decreased formation of a novel class of human blood platelets, called 'procoagulant platelets'. High levels of procoagulant platelets have been associated with transient ischemic attack and stroke.</li>
                            <li class="text-success">Enzymes inhibited by Rencofilstat, contribute to platelet activities.</li>
                            <li class="text-success">Treatment with Rencofilstat at pharmacologically relevant concentrations decreased membrane exposure of phosphatidylserine, a marker of procoagulant platelets. Importantly, Rencofilstat seemingly had no significant effect on platelet aggregation.</li>
                            <li class="text-success">Blocking procoagulant platelet formation may provide for a novel anti-thrombotic strategy, particularly in the prevention of certain types of strokes in which elevated levels of procoagulant platelets have been observed.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">September 2020 </span> <span class="text-warning font-monospace"> üìÅ [NIAID/NIH Study] Positive Antiviral Activity Against SARS Coronavirus-2</span>
                        </p>
                        <ul>
                            <li class="text-success">Rencofilstat treatment was found to inhibit production of infectious virus in these cells with almost five-times greater potency than the positive control compound in this study.</li>
                            <li class="text-success">Rencofilstat antiviral activity was due to specific effects on the virus.</li>
                            <li class="text-success">Rencofilstat decreased SARS-CoV-2 replication and infectious virus in vitro.</li>
                            <li class="text-success">The study conducted by NIAID further supports Rencofilstat as a potential drug candidate for COVID-19. Taken together, the antiviral properties of Rencofilstat in addition to the beneficial effects observed in acute lung injury are quite unique.</li>
                            <li class="text-success">The versatility we are observing with our lead drug candidate, is likely attributable to the mechanism of action of inhibiting several isoforms of cyclophilins.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">June 2020 </span> <span class="text-warning font-monospace"> üìÅ [Experimental Study] Efficacy In Kidney Fibrosis</span>
                        </p>
                        <ul>
                            <li class="text-info">[The study, which was conducted by SMC Laboratories in Tokyo, Japan, evaluated Rencofilstat in the Unilateral Ureteral Obstruction (‚ÄúUUO‚Äù) mouse model.]</li>
                            <li class="text-success">Kidney fibrosis in the Rencofilstat treated group was 42% lower as compared to vehicle treated mice (p=0.0006).</li>
                            <li class="text-success">Rencofilstat has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories in the United States, United Kingdom, France, and Japan.</li>
                            <li class="text-success">Rencofilstat down-regulates gene expression and decreases production and secretion of proteins important to fibrosis.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">March 2020 </span> <span class="text-warning font-monospace"> üìÅ [Translational Study] Efficacy In Human Idiopathic Pulmonary Fibrosis</span>
                        </p>
                        <ul>
                            <li class="text-info">[In the study, conducted by FibroFind Ltd. (Newcastle, UK), diseased lung tissue was obtained from an IPF patient undergoing a lung transplant and maintained for 6 days ex vivo by specialized, precision-cut culture techniques.]</li>
                            <li class="text-success">CRV431 dose-dependently decreased gene expression and secretion of every evaluated disease marker.</li>
                            <li class="text-success">CRV431 at 5 ¬µM decreased gene expression by an average of 45% (range 20-84% reduction), which was similar to the effects observed with pirfenidone (46% average reduction) dosed at concentrations 500-times greater than CRV431.</li>
                            <li class="text-success">The most potent secretion effect of 5 ¬µM CRV431 was a 61% reduction in the daily average production of the IPF biomarker, MMP7, which was twice the magnitude of nintedanib (31% reduction) and similar to pirfenidone (65% reduction).</li>
                            <li class="text-success">CRV431 exerted similar or greater effects than pirfenidone and nintedanib across many disease markers.</li>
                            <li class="text-success">The results reinforce that CRV431 has direct-acting anti-fibrotic activity that may be applicable to a range of fibrotic diseases and disorders, potentially even certain cancers.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">February 2020 </span> <span class="text-warning font-monospace"> üìÅ [Vitro Study] Anti-Fibrotic Potential Extend To Multiple Organs And Fibrotic Diseases</span>
                        </p>
                        <ul>
                            <li class="text-info">[The five cell types included in this study were lung fibroblasts from a patient with idiopathic pulmonary fibrosis (‚ÄúIPF‚Äù), cardiac fibroblasts, dermal (skin) fibroblasts, renal mesangial cells, and the LX2 hepatic stellate cell line]</li>
                            <li class="text-success">Rencofilstat can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells derived from five different organs.</li>
                            <li class="text-success">The advantage of Rencofilstat, based on our findings, is that its effects appear to be independent of the type of stimulatory signal. Therefore, Rencofilstat could be used to treat fibrosis without having to fully elucidate how the ECM-producing cells become over-activated.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">January 2020</span> <span class="text-warning font-monospace"> üìÅ [Experimental Study] Superior Antifibrotic Effect In Expanded Human Liver Study</span>
                        </p>
                        <ul>
                            <li class="text-info">[Expanded study with human precision cut liver slices ("PCLS"). The study was conducted by FibroFind, a spin-out contract research company from the Fibrosis Research Group at Newcastle University.]</li>
                            <li class="text-success">CRV431, prevented experimentally induced liver fibrosis to a greater extent than four other leading NASH drug candidates: obeticholic acid ("OCA", an FXR agonist), elafibranor (a PPARŒ±/Œ¥ agonist), resmetirom (a THR-Œ≤ agonist), and Aramchol (an SCD1 inhibitor).</li>
                            <li class="text-success">CRV431 was the only one of the five drug candidates that, on average, completely prevented TGF-Œ≤1- and PDGF-BB-induced fibrosis.</li>
                            <li class="text-success">CRV431 decreased gene expression and secretion of several markers of inflammation and fibrosis, including IL-6, MCP-1, collagen 1Œ±1, hyaluronic acid, and TIMP-1.</li>
                            <li class="text-success">We have evaluated dozens of investigational drugs from academia and industry, and CRV431 has been one of the most potent and consistent antifibrotic drug candidates that we've tested.</li>
                            <li class="text-success">Combining the direct antifibrotic actions of CRV431 with the indirect actions of other drug candidates likely represents the best opportunity for rapidly and effectively decreasing liver fibrosis in NASH.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">November 2019</span> <span class="text-warning font-monospace"> üìÅ [Experimental Study] Prevents Cirrhosis In Severe Liver Disease Model</span>
                        </p>
                        <ul>
                            <li class="text-info">[In this study, conducted by Physiogenex, S.A.S. (France), rats were administered the hepatotoxic compound, thioacetamide, for nine weeks to induce liver injury and fibrosis.]</li>
                            <li class="text-success">None of the 10 CRV431-treated rats developed cirrhosis.</li>
                            <li class="text-success">Anti-fibrotic activity of CRV431 was primarily responsible for attenuating the progression to cirrhosis over the duration of the study.</li>
                            <li class="text-success">Thioacetamide administration to rats is recognized to produce among the most severe liver disease of all experimental models. This model was a rigorous test of CRV431's anti-fibrotic activity.</li>
                            <li class="text-success">Every fibrosis study that we have conducted thus far, whether in animals or in human liver slices, has demonstrated CRV431's strong anti-fibrotic activity.</li>
                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace">November 2019</span> <span class="text-warning font-monospace"> üìÅ [Experimental Study] Reduces Liver Fibrosis In A Western Diet Model Of NASH</span>
                        </p>
                        <ul>
                            <li class="text-info">[Developed in the laboratory of Dr. Scott Friedman at Icahn School of Medicine at Mount Sinai, New York, this WD model employs a high-fat, high-fructose and high-cholesterol diet in combination with carbon tetrachloride ("CCl4") to cause significant fibrosis and hepatocellular carcinoma in mice.]</li>
                            <li class="text-success">CRV431 significantly decreased the extent of liver fibrosis in a highly regarded, Western Diet animal model of NASH.</li>
                            <li class="text-success">CRV431 reduced liver fibrosis by 82%.</li>
                            <li class="text-success">CRV431 also reduced the gain in weight caused by the Western Diet by 83%.</li>

                        </ul>
                        <div class="text-center my-4">‚åõ</div>
                        <p class="card-text">
                            <span class="font-monospace"></span> NIH RePORT <span class="text-warning font-monospace"> üìë Project #5R01AI143931-04: </span>
                        </p>
                        <p class="card-text text-center">
                            <span class="font-monospace">October 2023</span> <span class="text-warning font-monospace"> üìë Rencofilstat Demonstrates Anti-Cancer Activity In Hepatitis C-Assoicated Cancer Model</span>
                        </p>
                        <ul>
                            <li class="text-success">The study shows for the first time, cyclophilin inhibitor Rencofilstat represents a potent therapeutic agent for the treatment of HCV-induced HCC.</li>
                            <li class="text-success">Rencofilstat inhibits the development of HCV-induced HCC in mice even when added 16 weeks after infection when HCC is well established.</li>
                            <li class="text-success">Rencofilstat drastically reduces HCC progression independently of its anti-HCV activity.</li>
                            <li><a href="https://pubmed.ncbi.nlm.nih.gov/37896876/" target="_blank" class="link-underline-dark">Link: National Library of Medicine / PubMed</a></li>
                        </ul>

                        <p class="card-text text-center">
                            <span class="font-monospace">May 2021</span> <span class="text-warning font-monospace"> üìë NS5A And Cyclophilin Inhibitors Results In An Additive Anti-HCV Inhibition In Humanized Mice Without Development Of Resistance</span>
                        </p>
                        <ul>
                            <li class="text-success">Alisporivir and CRV431 display high anti-HCV efficacy both in vitro and in vivo.</li>
                            <li class="text-success">Alisporivir and CRV431 inhibit HCV infection by preventing the formation of complexes between host cyclophilin A (CypA) and HCV NS5A.</li>
                            <li class="text-success">High antiviral potency and their extended half-life in the body, CRV431 ~25 hours.</li>
                            <li class="text-success">Cyclophilin Inhibitor CRV431 alone significantly reduce both liver fibrosis and HCC in multiple NASH and NAFLD mouse models.</li>
                            <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136729/" target="_blank" class="link-underline-dark">Link: National Library of Medicine / PubMed</a></li>
                        </ul>

                        <p class="card-text text-center">
                            <span class="font-monospace">August 2020</span> <span class="text-warning font-monospace"> üìë CRV431 and NV556 Suppress Established HCV Infection In Humanized-Liver Mice</span>
                        </p>
                        <ul>
                            <li class="text-success">A single oral administration of CRV431 and NV556 to HCV-infected humanized-liver mice drastically reduced HCV blood levels.</li>
                            <li class="text-success">CRV431 and NV556 can totally suppress an established HCV infection in chimeric mice. CRV431 and NV556 6 weeks post-infection totally suppressed robust ongoing HCV replication 12 weeks post-infections.</li>
                            <li class="text-success">Daily oral administration of a high dose of CRV431 (50 mg/kg) for extended periods of time [14 to 30 weeks treatment] in mice did not induce unanticipated side effects.</li>
                            <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413547/" target="_blank" class="link-underline-dark">Link: National Library of Medicine / PubMed</a></li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
    </div>


    <footer class="py-3 mt-5 mb-3 access">
        <ul class="nav justify-content-center border-bottom pb-3 mb-3">
            <li class="nav-item"><a href="index.html" class="nav-link px-2 text-body-secondary">Homepage</a></li>
            <li class="nav-item"><a href="hepion.html" class="nav-link px-2 text-body-secondary">Hepion</a></li>
            <li class="nav-item"><a href="article.html" class="nav-link px-2 text-body-secondary">Article</a></li>
            <li class="nav-item"><a href="landscape.html" class="nav-link px-2 text-body-secondary">Landscape</a></li>
            <li class="nav-item"><a href="result.html" class="nav-link px-2 text-body-secondary">Data</a></li>
        </ul>
        <p class="text-center text-body-secondary">¬© 2023 CapriceYuri</p>
    </footer>
</body>

</html>